Skip to main content

Advertisement

Springer Nature Link
Log in

Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Apatinib is a novel inhibitor of vascular endothelial growth factor receptor-2. The goal of this study was to evaluate overall survival (OS) after a combination of transarterial chemoembolization (TACE) and apatinib in patients with advanced hepatocellular carcinoma (HCC) and to identify the factors affecting patient survival.

Methods

Fifty-one patients with advanced HCC who received TACE in combination with apatinib in our hospital from June 2015 to May 2017 were enrolled. The OS and progression-free survival (PFS) were calculated using the Kaplan-Meier method. The log-rank test and Cox regression model were used to determine the factors affecting OS.

Results

The median OS and PFS of the patients were 15 months and 10 months, respectively. The 1-, 2-, and 3-year survival rates were 64.7%, 23.5%, and 1.8%, respectively. Univariate survival analysis showed that patients with Child-Pugh A (P=0.006), reduction rate of proper hepatic artery (P=0.016), hand-foot syndrome (P=0.005), secondary hypertension (P=0.050), and without ascites (P=0.010) had a better OS. Multivariate analysis showed that hand-foot syndrome (P=0.014), secondary hypertension (P=0.017), and reduction rate of proper hepatic artery (P=0.025) were independent predictors of better OS.

Conclusion

TACE combined with apatinib is a promising treatment for advanced HCC. Hand-foot syndrome, secondary hypertension, and the reduction rate of proper hepatic artery were associated with a better OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018,391(10127):1301–1314

    Article  Google Scholar 

  2. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int, 2015,35(9):2155, 2166

    Article  Google Scholar 

  3. Bargellini I, Florio F, Golfieri R, et al. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol, 2017,37(4):438–444

    Google Scholar 

  4. Gaba, RC, Lokken RP, Hickey RM, et al. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol, 2017,28(9):1210–1223.e3

    Article  Google Scholar 

  5. Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Intervent Radiol, 2010,33(4):806–812

    Article  Google Scholar 

  6. Park JW, Kim YJ, Kim, DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol, 2019,70(4):684–691

    Article  CAS  Google Scholar 

  7. Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos, 2013,41(6):1195–1210

    Article  CAS  Google Scholar 

  8. Liang Q, Kong L, Du Y, et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. Exp Mol Med, 2019,51(76):1–11

    Article  CAS  Google Scholar 

  9. Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med, 2018,7(9):4570–4583

    Article  CAS  Google Scholar 

  10. Yang Z, Chen G, Cui Y, et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther, 2019,20(3):321–327

    Article  CAS  Google Scholar 

  11. Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther, 2017,18(6):433–438

    Article  CAS  Google Scholar 

  12. Chen S, Yu W, Zhang K. Comparison of the efficacy and safety of transarterial chemoembolization with and without apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer, 2018,18(1):1131

    Article  CAS  Google Scholar 

  13. Zhu Y, Feng B, Mei L, et al. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON, 2019,24(2):608–614

    PubMed  Google Scholar 

  14. Fan W, Yuan G, Fan H, et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: a multicenter retrospective study. Clin Ther, 2019,41(8):1463–1476

    Article  CAS  Google Scholar 

  15. Kan X, Liang B, Zhou G, et al. Transarterial Chemoembolization Combined with Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol, 2020,7(10):970

    Article  Google Scholar 

  16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018,69(1):182–236

    Article  Google Scholar 

  17. Zhou J, Sun HC, Wang Z, et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018,7(3):235–260

    Article  Google Scholar 

  18. Scott LJ. Apatinib: A Review in Advanced Gastric Cancer and Other Advance Cancers. Drugs, 2018,78:747–758

    Article  CAS  Google Scholar 

  19. Qiu L, Shukui Q, Shanzhi G. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: a randomized, placebo-controlled, doubleblind, phase 3 study. 2020, ASCO Annual Meeting Symposium: 303249

  20. Kok, VC, Chen Y, Chen Y, et al. Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers (Basel), 2019,11(7):985

    Article  CAS  Google Scholar 

  21. Chien SC, Chen CY, Cheng PN, et al. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer, 2019,8(3):186–202

    Article  CAS  Google Scholar 

  22. Sato Y, Nishiofuku H, Yasumoto T, et al. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol, 2018,29(8):1061–1067

    Article  Google Scholar 

  23. Liu J, Xie S, Duan X, et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. Cancer Chemother Pharmacol, 2020,85(1):69–76

    Article  CAS  Google Scholar 

  24. Zhou C, Yao Q, Zhang H, et al. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep, 2020,10(1):2964

    Article  CAS  Google Scholar 

  25. Ni JY, Kong J, Sun HL, et al. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol, 2018,25(4):423–429

    Article  Google Scholar 

  26. Liu C, Xing W, Si T, et al. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget, 2017,8(59):100734–100735

    Article  Google Scholar 

  27. Liu J, Xu J, Zhang W, et al. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. Acad. Radiol, 2019,27(5): 704–709

    Article  Google Scholar 

  28. Liao Z, Li F, Zhang C, et al. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med, 2019,51(3):1–11

    Article  CAS  Google Scholar 

  29. Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol, 2011,29(30):3960–3967

    Article  CAS  Google Scholar 

  30. Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension, 2018,71(2):e1–e8

    Article  CAS  Google Scholar 

  31. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol, 2008,26(18):2992–2998

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. The authors contributed equally to this study.

Authors and Affiliations

  1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Zi-yi Liu, Xue-feng Kan, Li-jie Zhang, Joyman Makamure, Qing Li, Dan Zhao, Guo-feng Zhou, Gan-sheng Feng, Chuan-sheng Zheng & Bin Liang

  2. Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China

    Zi-yi Liu, Xue-feng Kan, Li-jie Zhang, Joyman Makamure, Qing Li, Dan Zhao, Guo-feng Zhou, Gan-sheng Feng, Chuan-sheng Zheng & Bin Liang

Authors
  1. Zi-yi Liu
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Xue-feng Kan
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Li-jie Zhang
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Joyman Makamure
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Qing Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Dan Zhao
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Guo-feng Zhou
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Gan-sheng Feng
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Chuan-sheng Zheng
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Bin Liang
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Bin Liang.

Ethics declarations

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

This study was supported by the National Natural Science Foundation of China (No. 81771950, No. 81471765 and No. 81601578).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Zy., Kan, Xf., Zhang, Lj. et al. Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors. CURR MED SCI 42, 1015–1021 (2022). https://doi.org/10.1007/s11596-022-2620-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-022-2620-6

Key words